SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Patients with esophageal cancer that had metastatic lesions after been treated with
definitive surgery or chemoradiotherapy are being asked to participate in this study.
1. To observe immunity-mediated tumor response after Stereotactic Body Radiation
Therapy(SBRT) of a metastatic site in metastatic esophageal cancer patients.
2. To induce the efficacy (effectiveness) of a new combination of therapy, SBRT and
thymalfasin for heavily pretreated, metastatic esophageal cancer patients; This study
will help find out what effects (good or bad) the combination of radiotherapy and
thymalfasin has on metastatic esophageal cancer.